U.S. futures subdued as government shutdown stretches into second week
NEW YORK - Cancer prevention diagnostics company Lucid Diagnostics Inc. (NASDAQ:LUCD), currently valued at $124.82 million in market capitalization, announced Tuesday its intention to offer shares of common stock through an underwritten public offering. According to InvestingPro data, the company has seen a 52.17% price return over the past year despite challenging market conditions.
The Nasdaq-listed company, a subsidiary of PAVmed Inc. (NASDAQ:PAVM), plans to grant underwriters a 30-day option to purchase additional shares. Proceeds from the offering will support working capital and general corporate purposes, according to a company statement. This capital raise comes as InvestingPro analysis shows the company is quickly burning through cash, with an EBITDA of -$47.06 million in the last twelve months.
Canaccord Genuity LLC and BTIG, LLC are serving as joint bookrunners for the offering, with Maxim Group LLC acting as co-manager.
The company noted that completion of the offering remains subject to market conditions, with no assurance regarding its timing, size, or terms.
The offering is being conducted pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission in December 2022.
Lucid Diagnostics focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer. The company’s commercial products include the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device, which are designed for early detection of esophageal precancer. While revenue grew 14.74% in the last twelve months, the company faces profitability challenges with negative gross margins. Discover more insights about LUCD’s financial health and growth potential in the comprehensive Pro Research Report, available exclusively on InvestingPro.
The announcement was made in a press release statement issued by the company.
In other recent news, Lucid Diagnostics reported its second-quarter 2025 financial results, showing revenue of $1.2 million, which represents a year-over-year growth of approximately 19%. This revenue exceeded FactSet consensus estimates of $1.1 million but was slightly below Cantor Fitzgerald’s projection of $1.5 million. The company also posted an earnings per share (EPS) of -$0.10, surpassing the forecast of -$0.11. Meanwhile, BTIG reiterated its Buy rating and maintained a $2.00 price target after reviewing the Q2 results.
Additionally, Needham kept its Buy rating with a $3.00 price target following a positive Contractor Advisory Committee meeting by MolDX, highlighting the effectiveness of EsoGuard as a rule-out test for Barrett’s esophagus. BTIG also raised its price target to $2.50 from $2.00 after a favorable Centers for Medicare & Medicaid Services meeting discussing Medicare coverage for the EsoGuard test. Cantor Fitzgerald maintained its Overweight rating with a $3.00 price target following the financial results. These developments provide investors with insights into the company’s performance and analyst perspectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.